Pharmaceutical Products
842133-18-0;Canagliflozin;JNJ 24831754ZAE; JNJ 284
842133-18-0;Canagliflozin;JNJ 24831754ZAE; JNJ
Description
Canagliflozin(JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284) is an experimental drug being developed by Johnson & Johnson for the treatment of type 2 diabetes.Canagliflozin(JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284) is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.
http://www.chemscene.com/Canagliflozin.html
Read More
ChemScene, LLC
ChemScene Pharmaceutical chemical
Address: 11 Deer Park Drive, Suite 102A, Monmouth Junction, NJ 08852,
jersey, new jersey
United States, 07097
Tel: 732-484-9848
Fax: